Literature DB >> 17707678

Screening for cognitive deficits in Parkinson's disease with the Parkinson neuropsychometric dementia assessment (PANDA) instrument.

Elke Kalbe1, Pasquale Calabrese, Nils Kohn, Rüdiger Hilker, Oliver Riedel, Hans-Ulrich Wittchen, Richard Dodel, Jörg Otto, Georg Ebersbach, Josef Kessler.   

Abstract

Cognitive and affective dysfunctions are frequent but often neglected symptoms in Parkinson's disease (PD). We developed the screening tool Parkinson neuropsychometric dementia assessment (PANDA) with five cognitive tasks and a short depression questionnaire. Healthy subjects and patients without cognitive impairment (PD), mild cognitive disorder (PD-MCD), or dementia (PDD) were examined. The cognition part had a specificity of 91% and a sensitivity of 90% for PDD and 77% for PDD plus PD-MCD patients. The mood questionnaire also had high sensitivity and specificity. We conclude that the PANDA is an economical, easy-to-use and sensitive tool to detect neuropsychological dysfunctions in PD patients in clinical practice.

Entities:  

Mesh:

Year:  2007        PMID: 17707678     DOI: 10.1016/j.parkreldis.2007.06.008

Source DB:  PubMed          Journal:  Parkinsonism Relat Disord        ISSN: 1353-8020            Impact factor:   4.891


  60 in total

Review 1.  Gender differences in Parkinson's disease: clinical characteristics and cognition.

Authors:  Ivy N Miller; Alice Cronin-Golomb
Journal:  Mov Disord       Date:  2010-12-15       Impact factor: 10.338

Review 2.  Mild cognitive impairment in Parkinson's disease.

Authors:  J G Goldman; I Litvan
Journal:  Minerva Med       Date:  2011-12       Impact factor: 4.806

Review 3.  Sharpening the boundaries of Parkinson-associated dementia: recommendation for a neuropsychological diagnostic procedure.

Authors:  Marc R Bothe; Ingo Uttner; Markus Otto
Journal:  J Neural Transm (Vienna)       Date:  2010-01-30       Impact factor: 3.575

4.  A recommended scale for cognitive screening in clinical trials of Parkinson's disease.

Authors:  Kelvin L Chou; Melissa M Amick; Jason Brandt; Richard Camicioli; Karen Frei; Darren Gitelman; Jennifer Goldman; John Growdon; Howard I Hurtig; Bonnie Levin; Irene Litvan; Laura Marsh; Tanya Simuni; Alexander I Tröster; Ergun Y Uc
Journal:  Mov Disord       Date:  2010-11-15       Impact factor: 10.338

Review 5.  Parkinson's disease: the quintessential neuropsychiatric disorder.

Authors:  Daniel Weintraub; David J Burn
Journal:  Mov Disord       Date:  2011-05       Impact factor: 10.338

Review 6.  MDS Task Force on mild cognitive impairment in Parkinson's disease: critical review of PD-MCI.

Authors:  Irene Litvan; Dag Aarsland; Charles H Adler; Jennifer G Goldman; Jaime Kulisevsky; Brit Mollenhauer; Maria C Rodriguez-Oroz; Alexander I Tröster; Daniel Weintraub
Journal:  Mov Disord       Date:  2011-06-09       Impact factor: 10.338

7.  [Implementation of the German S3 guidelines on dementia in clinical practice: wish or reality?]

Authors:  H Lohmann; F Kulessa; H Holling; A Johnen; S Reul; G Lueg; T Duning
Journal:  Nervenarzt       Date:  2017-08       Impact factor: 1.214

8.  Cognitive impairment in 873 patients with idiopathic Parkinson's disease. Results from the German Study on Epidemiology of Parkinson's Disease with Dementia (GEPAD).

Authors:  Oliver Riedel; Jens Klotsche; Annika Spottke; Günther Deuschl; Hans Förstl; Fritz Henn; Isabella Heuser; Wolfgang Oertel; Heinz Reichmann; Peter Riederer; Claudia Trenkwalder; Richard Dodel; Hans-Ulrich Wittchen
Journal:  J Neurol       Date:  2008-01-22       Impact factor: 4.849

9.  Validity of the MoCA and MMSE in the detection of MCI and dementia in Parkinson disease.

Authors:  S Hoops; S Nazem; A D Siderowf; J E Duda; S X Xie; M B Stern; D Weintraub
Journal:  Neurology       Date:  2009-11-24       Impact factor: 9.910

10.  Lewy body dementia and Parkinson's disease with dementia.

Authors:  Richard Dodel; Ilona Csoti; Georg Ebersbach; Gerd Fuchs; Matthias Hahne; Wilfried Kuhn; Matthias Oechsner; Wolfgang Jost; Heinz Reichmann; Jörg B Schulz
Journal:  J Neurol       Date:  2008-09       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.